TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
Picca A, Di Stefano AL, Savatovsky J, Ducray F, Chinot O, Moyal EC, Augereau P, Le Rhun E, Schmitt Y, Rousseaux N, Yepnang AMM, Estellat C, Charbonneau F, Letourneur Q, Branger DF, Meyronet D, Fardeau C, Mokhtari K, Bielle F, Iavarone A, Sanson M.
Picca A, et al. Among authors: fardeau c.
Neurooncol Adv. 2024 May 20;6(1):vdae068. doi: 10.1093/noajnl/vdae068. eCollection 2024 Jan-Dec.
Neurooncol Adv. 2024.
PMID: 38813112
Free PMC article.